Dow Jones
38.852,27 +176,59 (+0,46%) Nasdaq
16.349,25 +192,92 (+1,19%) Nikkei 225
38.688,66 +452,59 (+1,18%) EUR/USD
1,0767 -0,0007 (-0,06%) Bitcoin EUR
59.165,57 -202,62 (-0,34%) CMC Crypto 200
1.369,81 +57,18 (+4,36%)
Inozyme Pharma, Inc. (INZY)
Dopo ore:
| Chiusura precedente | 4,7400 |
| Aperto | 4,8000 |
| Denaro | 4,8600 x 200 |
| Lettera | 4,9100 x 100 |
| Min-Max giorno | 4,7601 - 4,9000 |
| Intervallo di 52 settimane | 2,6890 - 7,7950 |
| Volume | |
| Media Volume | 703.190 |
| Capitalizzazione | 301,855M |
| Beta (5 anni mensile) | 1,37 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,4100 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 20,33 |
GlobeNewswireInozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI), which is caused by mutations in the ENPP1 or ABCC6 genes, in the Genomic England’s Generation Study. This research initiative, embedded within the UK
- GlobeNewswire
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada. Details of the presentations are
- GlobeNewswire
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) trial - - INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, Sept. 26,
